In today's digital era , the widespread use of electronic devices has profoundly changed people's lifestyles. However, this convenience has also brought severe public health challenges—the sharp rise in the incidence of myopia. In China, myopia is increasingly affecting younger age groups and leads to higher degrees of severity, which is worrisome. According to the 2020 National Myopia Survey, the overall myopia rate among Chinese children and adolescents reached 52.7%, with the rate among high school students as high as 80.5%. The International Myopia Institute (IMI) predicts that China's myopia rate will reach an astonishing 80% to 90% by the middle of this century. Such a high incidence of myopia not only affects individuals' quality of life, but also imposes substantial pressure on the healthcare system. Despite the availability of various methods for myopia prevention and control—such as spectacles, orthokeratology lenses, pharmacological treatments, and surgical interventions—these options possess obvious limitations including limited efficacy, high costs, and potential risks, thereby lacking a safe, effective, and long-term solution.

The increasing global demand for coffee has led to a substantial accumulation of coffee grounds, presenting a significant waste management challenge. Current estimates suggest that millions of tons of coffee grounds are produced annually, a volume that could fill 2 to 3 Bird’s Nest National Stadiums in Beijing, which hosted the 2008 Olympics. According to statistics from the International Coffee Organization (ICO), every ton of processed coffee beans generates approximately 650 kilograms of coffee grounds. These grounds, often discarded as waste, pose environmental risks and represent a missed opportunity for resource recovery, particularly in the extraction of valuable compounds such as caffeine. Finding efficient methods to recycle and repurpose coffee grounds is therefore a pressing global issue.

The dual challenges of increasing coffee ground waste and the rising incidence of myopia call for an innovative solution. There is an urgent need for innovative and sustainable approaches for myopia prevention and control.

To address this challenge, our team has focused on 7-methylxanthine (7-MX), a compound proven to effectively mitigate the progression of myopia. 7-MX possesses high safety and efficacy, but its widespread application is limited by its high production costs. In response to the growing environmental concerns for the disposal of coffee ground waste, we have developed an innovative method to extract caffeine from discarded coffee grounds as a raw material for 7-MX production. This not only addresses the issue of coffee ground accumulation but also adds a value to an otherwise wasted resource. We have innovatively constructed an frmAB-FDH cofactor recycling system to optimize the production method of 7-MX via the NdmABD pathway in Escherichia coli, which plays a critical role in enhancing efficiency and reducing by-product accumulation. Through this technology, we have significantly increased the yield of 7-MX, reduced its production costs, and resolved the issues of intermediate accumulation and low production efficiency. More importantly, our process eliminates the harmful formaldehyde generated during 7-MX production, achieving an environmentally friendly production workflow that embodies the concept of sustainable development. This not only aligns with national environmental protection policies but also sets a new benchmark for the biopharmaceutical industry. By utilizing coffee grounds in this process, we further contribute to circular economy principles and reinforce our commitment to sustainability.

Looking ahead, we plan to further optimize the production process of 7-MX to improve its yield and purity, and ensure the stability and consistency of product quality. We are actively promoting the collaborations with pharmaceutical companies and medical institutions to accelerate the industrialization of our technology and achieve a large-scale production and market deployment.

Looking ahead, we plan to further optimize the production process of 7-MX to improve its yield and purity, and ensure the stability and consistency of product quality. We are actively promoting the collaborations with pharmaceutical companies and medical institutions to accelerate the industrialization of our technology and achieve a large-scale production and market deployment.

Simultaneously, we intend to conduct clinical trials and application studies to validate the safety and efficacy of our product, laying a solid foundation for product registration and market approval. We will also continuously monitor industry trends and technological advancements, and foster innovation to maintain our technological leadership.

In terms of market promotion, we will develop comprehensive marketing strategies, and leverage multiple channels to increase product awareness and influence and meet the needs of a broad consumer base. Furthermore, we aim to actively participate in the formulation and improvement of industry standards to promote the healthy development of the myopia prevention and control field.

At the same time, our team envisions expanding the application of coffee ground recycling to create a fully sustainable production model for 7-MX. By scaling up the extraction of caffeine from coffee grounds, we aim to significantly reduce industrial waste while utilizing this abundant resource for high-value pharmaceutical production. This approach not only alleviates the environmental burden posed by millions of tons of discarded coffee grounds but also aligns with global efforts to promote a circular economy. Our commitment to sustainable development drives us to continuously innovate in green production processes minimize the ecological impact and promote the responsible use of natural resources. This initiative will not only set new standards in biopharmaceutical manufacturing but also contribute to long-term environmental sustainability and resource efficiency.

Through these efforts, we aspire to make substantial contributions to the cause of myopia prevention and control, and help more individuals improve their visual health and life quality. Meanwhile , we hope to leverage this opportunity to drive innovation in the biopharmaceutical industry, and achieve a win-win situation of economic and social benefits.

The global myopia prevention and control market is facing significant growth opportunities, especially with the rising incidence of myopia among children and adolescents, which has become an urgent public health concern. According to the 2020 National Survey on Children and Adolescents’ Myopia in China, the myopia rate among Chinese youth has reached 52.7%, with a staggering number of 80.5% among high school students. Meanwhile, the global myopia treatment market is projected to reach USD 32.98 billion by 2030, with a stable annual growth rate, particularly driven by the expanding demand in the Asia-Pacific region. Existing myopia control solutions, such as eyeglasses, contact lenses, orthokeratology lenses, surgical treatments, and pharmaceutical options, present significant limitations. These solutions fail to meet the market demand for safe, long-term, and effective methods to manage myopia progression. Consequently, there is an urgent need for an innovative product to address these unmet needs.

In addition to the unmet need for effective myopia control, the recycling of coffee grounds, a major environmental concern, also presents a significant market opportunity. Global coffee ground production is estimated to reach millions of tons annually, contributing to substantial waste. Each ton of processed coffee generates approximately 650 kilograms of coffee grounds, which are often discarded without proper recycling solutions. Addressing this issue by utilizing coffee grounds in pharmaceutical applications, such as extracting caffeine for 7-MX production, offers a sustainable solution.

7-MX, as a novel myopia control product, offers the features such as safety, long-term use, and proven effectiveness in slowing myopia progression, which is especially suitable for children and adolescents. Supported by a well-structured market entry strategy, 7-MX application will not only collaborate with research institutions, hospitals, and schools to enhance product awareness but also implement both online and offline promotional efforts to ensure rapid penetration into the domestic market. Moreover, the use of recycled coffee grounds in the production process emphasizes the project’s commitment to environmental sustainability, turning waste into valuable resources and contributing to a circular economy. The team is also committed to fulfilling social responsibility by promoting long-term education on myopia prevention and employing eco-friendly production and packaging solutions to ensure the project’s sustainable development.

Given the robust growth trajectory of the global myopia control market, the environmental benefits of coffee ground recycling, and the innovative nature of the 7-MX product, it holds substantial potential for success in this market. The future outlook for market expansion is highly promising.

The current myopia prevention and control market faces multiple challenges, particularly with the rising prevalence of myopia among children and adolescents. Existing solutions, such as eyeglasses, contact lenses, orthokeratology lenses, surgical correction, and pharmaceutical treatments, all exhibit distinct limitations.

Eyeglasses only temporarily improve vision without slowing the progression of myopia. Long-term wear can impose psychological burdens on adolescents, affecting their appearance and hindering daily activities such as sports.

Contact lenses, while providing better visual clarity and convenience, require rigorous maintenance. Improper care can lead to eye infections, and prolonged use poses significant risks, especially for children and adolescents.

Orthokeratology lenses temporarily reshape the cornea overnight, allowing for clear vision during the day. However, the high cost of these lenses, combined with the risk of corneal infection if not worn or cleaned properly, poses significant drawbacks. Additionally, these lenses must be used consistently over the long term, which may lead to adherence challenges for users.

Surgical treatments like LASIK offer permanent vision correction but are not suitable for adolescents due to the irreversible nature of the procedure and post-surgery risks, such as dry eye and night vision issues. The procedure is also not recommended for children, making it a less feasible option for younger patients.

Pharmaceutical treatments, such as atropine eye drops, have shown some efficacy in slowing myopia progression. However, long-term use can lead to side effects like pupil dilation, glare, and accommodation paralysis. Moreover, the long-term safety of these treatments has yet to be fully validated.

As a result, the market urgently requires a safe, effective, and long-term solution that can control myopia progression while avoiding the high costs and health risks associated with current treatments. This represents a significant unmet need, which 7-MX has the potential to address, filling this critical gap in the myopia prevention and control landscape.

The first potential customers of 7-MX are primarily concentrated in the children and adolescent demographic, particularly those at high risk of progressive myopia. According to the 2020 National Survey on Children and Adolescents' Myopia in China, the myopia rate among Chinese youth has reached 52.7%, with high school students showing an even higher prevalence of 80.5%. This group is at a critical stage of learning and development, and myopia not only affects their visual health but also significantly impacts their academic performance and future career choices. As a result, both parents and schools have a pressing need for an effective, safe myopia prevention solution. Existing options, such as eyeglasses, contact lenses, and orthokeratology lenses, only provide temporary vision correction without effectively slowing the progression of myopia, while their use often inconveniences daily activities. In contrast, the long-term efficacy of 7-MX in mitigating myopia progression makes it highly appealing to this target audience.

7-MX’s oral administration is particularly well-suited for children and adolescents, avoiding the complications and risks associated with the care and maintenance required for contact lenses or orthokeratology lenses. Compared to surgical options, 7-MX is non-invasive and highly safe, making it ideal for long-term use. The product’s ease of use, without the need for daily wear, allows users to maintain their regular lifestyle, including sports and social activities, which is especially beneficial for those who are sensitive about appearance or lead active lives. Moreover, parents, as the primary decision-makers, will find 7-MX appealing due to its safety profile and long-term effectiveness. The lack of significant side effects aligns with parents' concerns for the health and well-being of their children.

Additionally, schools and educational institutions will be key partners in promoting the product, as health education programs can introduce 7-MX to more parents and students. With its innovative treatment mechanism, safety, and convenience, 7-MX is poised to quickly capture the attention of both parents and educational institutions, becoming the ideal solution for preventing myopia progression in adolescents and driving early market penetration.

The global myopia treatment market is experiencing significant growth. According to Data Bridge Market Research, the market is projected to reach USD 32.98 billion by 2030. This growth is primarily driven by the increasing global incidence of myopia, particularly among children and adolescents. The data indicate that from 2023 to 2030, the compound annual growth rate (CAGR) of the global myopia treatment market will remain steady, with all regional markets continuing to expand.

Regionally, the Asia-Pacific is expected to account for the largest market share, making it the primary driver of global myopia treatment market growth. This is particularly due to the high myopia prevalence in countries like China and India, where youth myopia rates are alarmingly high, coupled with large populations. As lifestyle changes and increased use of electronic devices continue to escalate myopia prevalence, the demand for innovative treatment solutions in the region will keep rising. The North American and European markets are also projected to maintain robust growth rates, largely attributed to technological advancements, improved healthcare systems, and growing consumer awareness of eye health.

While South America, the Middle East, and Africa have relatively small market shares, these regions are expected to see notable growth as awareness of eye care and myopia treatment increases. With healthcare infrastructure steadily improving, these regions show significant market potential in the coming years.

Overall, the global myopia treatment market will continue its steady expansion over the next decade , with the market size increasing year by year from 2023 to 2030. This growth trend presents a significant opportunity for the introduction of 7-MX, particularly in addressing the myopia control needs of children and adolescents. With its long-lasting and safe characteristics, 7-MX is well-positioned to meet the urgent demand for effective myopia management solutions. As the global population continues to age and the increased use of electronic devices, myopia will remain a pressing issue, driving sustained demand in the market.

Strong Policy Support: In recent years, the government has significantly increased its emphasis on myopia prevention and control, issuing a series of policy documents and action plans, such as the Implementation Plan for Comprehensive Prevention and Control of Myopia in Children and Adolescents. These policies clearly outline the goals and measures for myopia prevention, providing a favorable developing environment and policy guarantee for the industry. This support has facilitated the orderly progress in myopia prevention efforts across various regions and institutions.

Technological Innovation Driving Industry Progress: The myopia prevention and control industry is highly technology-intensive, with scientific innovation serving as a crucial driver of its development. The application of new technologies such as artificial intelligence, big data, and gene editing has led to breakthrough advancements in the field. For example, the development and deployment of intelligent vision screening devices have made vision tests more convenient and accurate. Explorations in gene editing for myopia prevention offer new possibilities for genetic-level interventions. These technological innovations not only enhance the overall standards of myopia prevention but also provide companies with a competitive edge in the market.

Robust Market Demand: The severity of myopia and the rising public health awareness have led to a strong demand for myopia prevention products and services. The continuously increasing myopia rates among children and adolescents, in particular, have heightened the demand from parents and schools. This growing market demand presents expansive development opportunities and market potential for the industry.

Complete Industry Chain: The myopia prevention and control industry encompasses multiple sectors, including medical device manufacturing, pharmaceutical research and development, ophthalmic services, and vision care products, which form a relatively complete industry chain. Collaboration among enterprises in various segments—such as medical device manufacturers, pharmaceutical companies, ophthalmic clinics and hospitals, and vision care product manufacturers—enhances overall efficiency and competitiveness through synergy.

High Technical Barriers: The industry involves multiple fields such as medicine and technology, resulting in high technical thresholds. The development of high-precision vision screening devices, new myopia correction equipment, and myopia control drugs requires substantial research and development investment and technological accumulation. Small and medium-sized enterprises and startups often face significant challenges in technological development, making it difficult to compete with internationally renowned companies.

Significant Capital Investment Required: Research and development, along with market promotion in the myopia prevention industry, demand considerable capital. For instance, developing high-precision vision screening devices and new correction equipment requires substantial R&D funding. New drug development and clinical trials necessitate long-term financial support, and market promotion and channel building also require significant investment. For enterprises with weaker financial strength, capital requirements become a major limiting factor in their development.

Intense Market Competition: As more enterprises enter the myopia prevention market, competition intensifies. Internationally renowned companies have strong competitive advantages in technology and branding, while domestic enterprises may excel in market promotion and channel development. Facing fierce market competition, companies need to continuously enhance their technological capabilities and service quality to maintain a competitive edge.

Strict Regulatory Requirements: Myopia prevention involves medical and health fields with stringent regulatory demands. Vision screening devices and correction equipment must undergo rigorous quality testing and certification processes. Myopia control drugs require lengthy clinical trials and approval procedures. While these regulatory requirements help ensure product and service safety and efficacy, they also increase research and development costs and market entry barriers for enterprises.

Policy-Driven Industry Development: With the government's increasing emphasis on myopia prevention, more supportive policies and measures are expected to be introduced, creating a favorable policy environment for industry development. Policies such as financial subsidies, tax incentives, and research funding support will help enterprises and research institutions increase R&D investment, launch more innovative products and services, and elevate the industry's overall standards.

Growing Market Demand: As the problem of myopia worsens and public health awareness rises, the demand for myopia prevention products and services will continue to grow. For example, the prevention needs of children and adolescents will become a primary market growth point, and families and schools will increasingly demand vision care products and services. This provides extensive development space and market opportunities for related enterprises and institutions.

Technological Advancements Bring New Opportunities: The continuous development of new technologies such as artificial intelligence, big data, and gene editing will usher in a wave of technological innovation in the myopia prevention field. For instance, precision management and personalized treatment of myopia patients can be achieved through big data analysis and AI technology. Gene editing technology offers possibilities for preventing and treating myopia at the genetic level. The application of these new technologies will inject new momentum into industry development.

International Cooperation and Exchange: Myopia is a global public health issue, and strengthening international cooperation is crucial for enhancing myopia prevention levels. With the acceleration of globalization, international cooperation in the myopia prevention field will deepen. For example, conducting international joint research projects to tackle technological challenges, introducing and promoting advanced international technologies and products, and participating in international academic conferences and technical exchange activities to share successful experiences and best practices.

Technical Risks: Technological research and development in the myopia prevention field carry high risks. For instance, new drug development requires long-term clinical trials and approval processes with significant uncertainties. The development of high-precision vision screening devices and new correction equipment also faces technical difficulties and risk of failure. These technical risks not only increase enterprises' R&D costs and market risks but may also affect their market competitiveness.

Market Risks: The intense competition in the myopia prevention market leads to high market risks. International companies have strong advantages in technology and branding, while domestic companies compete fiercely in market promotion and channel development. To remain competitive, enterprises need to continuously improve their technological level and service capabilities. Additionally, changes in market demand and consumer preferences may impact companies' market performance.

Regulatory Risks: Myopia prevention involves medical and health sectors with strict regulatory requirements. Devices and drugs need to undergo rigorous quality testing and lengthy approval processes, increasing R&D costs and market entry barriers. Changes and uncertainties in regulatory policies may also affect business operations, requiring companies to closely monitor policy developments and adjust strategies accordingly.

Financial Risks: The industry's research and development and market promotion require substantial capital investment. Developing high-precision devices, conducting clinical trials for new drugs, and building market channels all demand long-term financial support. For enterprises with weaker financial strength, financial risks become a significant limiting factor. Difficulties in financing or cash flow interruptions may restrict enterprise development, making financial risk a crucial factor constraining industry growth.

The market entry strategy for 7-MX centers on a multi-faceted approach, combining strategic partnerships, a scientifically driven promotional plan, and a strong commitment to social responsibility. These components ensure the product’s swift penetration into the myopia control market and widespread impact. Initially, 7-MX will leverage collaborations with ophthalmic hospitals, research institutions, and biotechnology companies to secure robust support for its clinical trials and product certification. This not only enhances the product’s credibility in the medical field but also bolsters its reputation in the market as a trusted and scientifically validated solution.

Moreover, a key element of the promotional strategy is the eye exercise video co-produced with Jilin University. This video serves as a powerful marketing tool, distributed widely through online platforms and integrated into health education programs in schools and communities. The video aims to raise public awareness of myopia prevention and control, particularly among children, adolescents, and their parents, who represent a key target demographic. By providing educational content alongside the introduction of 7-MX, the video fosters greater understanding and acceptance of the product’s benefits.

Through this comprehensive strategy, 7-MX is positioned to quickly establish a strong market presence, while also contributing to broader public health initiatives.

The promotion strategy for 7-MX combines both online and offline channels to achieve comprehensive market penetration. Offline, the team will collaborate with schools, communities, and healthcare institutions to integrate 7-MX as a vital component of myopia prevention programs. With endorsements from ophthalmologists, teachers, and parents, 7-MX will quickly gain traction among the youth demographic. At the same time, online promotion will be carried out through e-commerce platforms, social media, and health websites, providing clear and scientific information about myopia prevention and product education to enhance consumer trust in the brand.

In terms of pricing, 7-MX will adopt a competitive pricing strategy to ensure the product is accessible to a wide range of families. The product will be available in various formats and packaging options to cater to the diverse needs of different consumer groups. By leveraging resources from corporate partnerships, the team will streamline production processes, reduce operational costs, and maintain a competitive pricing advantage.

Moreover, social responsibility is a key element of 7-MX’s market promotion. The team is committed not only to product sales but also to the long-term education and awareness of myopia prevention. As part of this initiative, the team will launch public myopia prevention campaigns, offering free screenings and educational workshops in schools and communities. These efforts aim to reach 30% of schools and communities nationwide, fostering collaboration with schools and government health programs. This initiative will position 7-MX as a crucial part of public health efforts, helping parents and students adopt scientific eye care habits and preventative methods, contributing to the healthy development of children and adolescents.

In line with its commitment to sustainability, the team will use environmentally friendly materials in production and packaging, reducing carbon emissions. This approach not only aligns with national green development strategies but also underscores the team’s dedication to environmental protection. Additionally, the team will implement a product recycling program to ensure expired or discarded products are disposed of responsibly, further minimizing environmental impact.

Through these initiatives, 7-MX will rapidly capture the domestic market while laying a strong foundation for international expansion. The combination of a multi-faceted promotion strategy, commitment to social responsibility, and a focus on sustainable production will position 7-MX not only as a commercially successful product but also as a leader in the healthy development of the myopia prevention industry.

7-MX eye drops are designed for simple, daily use, particularly for adolescents and individuals with a high risk of myopia. The recommended dosage is 1-2 drops per eye, used consistently during periods of high visual demand. To ensure safety and effectiveness, users should follow proper hygiene before application, avoid touching the dropper, and store the product appropriately.

7-MX works as a non-selective adenosine receptor antagonist, regulating dopamine and acetylcholine transmission. This mechanism slows eye growth, preventing scleral thinning and axial elongation, key factors in myopia progression. Studies show its effectiveness in significantly slowing myopia development, particularly in young users.

Beyond therapeutic benefits, 7-MX reflects our commitment to social responsibility. With a preservative-free formula, it minimizes irritation while promoting eye care awareness. This aligns with our mission to support public health and environmental sustainability, contributing to the long-term well-being of future generations.

7-MX eye drops developed by our team represent an innovative solution to the growing global problem of myopia, particularly among children and adolescents. Myopia has reached epidemic levels worldwide, significantly impacting individuals' quality of life and increasing the risk of more serious eye conditions such as cataracts, glaucoma, and retinal detachment. As current treatments like corrective glasses, contact lenses, and refractive surgery primarily address the symptoms rather than the progression of myopia, there is a critical need for solutions that can effectively slow down the condition's advancement, particularly in younger populations.

7-MX, a non-selective adenosine receptor antagonist, has demonstrated promising results in mitigating the progression of myopia by inhibiting scleral thinning and the elongation of the eyeball. This product is specifically designed for long-term use, making it highly suitable for children and adolescents, whose eye growth is more rapid. Additionally, the non-invasive nature of 7-MX eye drops offers a significant advantage over surgical options, providing a safer and more accessible solution for managing myopia.

Our product is produced using cutting-edge biosynthetic technology, ensuring both high efficiency and environmental sustainability. Through the application of this advanced technology, 7-MX eye drops offer a safe, effective, and environmentally friendly option for myopia prevention, with the potential to make a meaningful impact on public health.

7-MX eye drops developed by our team possess significant innovation and environmental sustainability at their core. As a non-selective adenosine receptor antagonist, 7-MX effectively slows the progression of myopia by blocking adenosine receptors, which in turn inhibits scleral thinning and axial elongation of the eyeball. This mechanism is particularly beneficial for children and adolescents, who are at greater risk for rapid myopia progression.

In terms of production technology, we employ advanced synthetic biology techniques, and have innovatively constructed the frmAB-FDH cofactor recycling system, which optimizes the 7-MX production pathway in Escherichia coli. This technology has significantly increased the yield of 7-MX, reduced production costs, and resolved issues of intermediate accumulation and low production efficiency.

Regarding environmental sustainability, our team introduced a formaldehyde dehydrogenase gene system, which converts formaldehyde generated during the reaction into carbon dioxide, thereby preventing formaldehyde accumulation and environmental pollution. This green production platform not only eliminates harmful substances but also generates reducing power, providing essential energy for the reaction, further increasing 7-MX yield. Additionally, we have integrated the use of recycled coffee grounds as a sustainable source of caffeine for 7-MX production, addressing the environmental burden posed by the large-scale disposal of coffee grounds. By extracting caffeine from this abundant waste material, we contribute to waste reduction while enhancing resource efficiency in the production process. In experiments, the strain containing the formaldehyde dehydrogenase system demonstrated a 173.9% improvement in caffeine conversion compared to the strain without the system, highlighting a significant efficiency advantage. This technological breakthrough achieves both environmental protection and efficient production, providing a strong foundation for the large-scale and sustainable production of 7-MX, while promoting the circular use of natural resources through coffee ground recycling and underscoring the team’s commitment to sustainability.

In this study, our team utilized the NDM enzyme system from Pseudomonas CBB5. During the initial attempts, we constructed the gene pathway by following the gene cluster sequence from CBB5 and successfully introduced the synthetic gene cluster into engineered Escherichia coli. After inducing the culture, we placed the engineered bacteria in a solution containing 1 mM caffeine for overnight incubation, followed by HPLC analysis. The resulting yields were 0.06 mM 7-Methylxanthine and 0.31 mM theobromine, with a conversion rate of 6%, which was only 0.27% of the reported yield. Therefore, direct use of the gene cluster did not result in high yields.

Based on synthetic biology optimization principles, our team first analyzed the genes and optimized the gene sequence. Under the same conditions, we were able to convert 0.27 mM of caffeine substrate into 7-Methylxanthine from 1 mM caffeine, achieving a conversion rate of 27% without accumulation of intermediate theobromine, demonstrating that optimizing the gene sequence could significantly enhance conversion efficiency. Additionally, by modifying key genes, truncating non-essential parts, and reducing metabolic pressure on the bacteria, we increased protein expression. This resulted in further improvements, as the modified strain converted 0.655 mM caffeine from 1 mM substrate into 7-Methylxanthine, achieving a 143% increase in yield.

Verification of the product expressed by the modified strain revealed that a large amount of inclusion bodies (inactive protein) formed during the induced expression . To enhance the solubility of the target protein and improve reaction efficiency, we optimized induction conditions. After comparing several conditions, we identified an optimal condition under which 1 mM caffeine substrate could be fully converted to 7-Methylxanthine. This optimization led to a 35% increase in yield, with a total output of 44.84% of the reported yield.

Further analysis of the chemical reaction allowed us to optimize the process by adjusting bacterial concentration, substrate concentration, reducing power, and oxygen levels. With the optimized bacterial and substrate concentrations and improved oxygen supply, the engineered E. coli was able to completely convert 4 mM caffeine into 7-Methylxanthine. During process optimization, the yield was increased by 400%, reaching 179.4% of the reported yield.

After confirming the optimal reaction conditions through preliminary experiments, we scaled up the fermentation in a 5 L fermenter. Caffeine substrate (60 mM) was added in batches under optimal conditions, and after a 20-fold dilution, the yield was measured using HPLC. The final results showed that 50.21 mmol of 60 mmol caffeine was converted into 7-MX, achieving a conversion rate of 83.7%, which was 2252.1% improvement of the reported value.

During the purification process, we discovered that density gradient centrifugation could efficiently separate the solid-liquid phase and isolate 7-Methylxanthine crystals from other impurities. This simple and efficient method achieved a recovery rate close to 95%, with a theoretical yield of 8.37 g/L. HPLC analysis revealed that the product purity was close to 99%, which is higher than the standard products currently available on the market.

7-MX, as the first reported drug in the methylxanthine family proven to effectively alleviate myopia, possesses unique competitive advantages in the market. Our product utilizes high-purity, high-efficacy 7-MX, subjected to rigorous quality testing and validation to ensure its safety and effectiveness. Compared to traditional myopia correction methods, 7-MX can slow the progression of myopia at its source, featuring non-invasiveness, suitability for long-term use, and high safety. Additionally, our green production process not only reduces production costs but also demonstrates our commitment to environmental protection, aligning with the current societal demand for sustainable development. A key feature of our production method is the innovative use of recycled coffee grounds as a source of caffeine, effectively turning a significant waste product into a valuable resource. By incorporating coffee ground recycling, we address both environmental waste issues and resource sustainability, offering a truly eco-friendly solution.

Through the integration of technological innovation and environmental principles, 7-MX provides consumers with a safe, effective, and eco-friendly solution for myopia control.

Our marketing strategy centers on precise targeting and multi-channel promotion, aiming to meet the needs of different customer groups. The primary target customers include children and adolescents—a high-incidence group for myopia whose parents are highly concerned about their visual health—high visual-demand populations such as white-collar workers and students who extensively use electronic devices, and individuals with a genetic predisposition to myopia who wish to prevent its onset or progression.

We will adopt a combination of online and offline sales channels. Online channels include our own e-commerce platform, major e-commerce platforms such as Tmall and JD.com, and social media shopping platforms like WeChat Mini Programs, providing consumers with convenient online purchasing options. Offline channels involve collaborations with large chain pharmacies, ophthalmic hospitals, and optical stores to set up product counters or dedicated areas.

In terms of promotion strategies, online promotion will utilize social media platforms such as WeChat, Weibo, and TikTok for content marketing, inviting professional ophthalmologists and Key Opinion Leaders (KOLs) for scientific education and product endorsements. We will conduct live broadcasts and interactive activities to enhance brand awareness and user engagement. Offline activities include hosting public welfare lectures on myopia prevention and campus health events, collaborating with schools and communities to provide free vision screening and health consultations, thereby enhancing the brand's social influence. Additionally, we will establish strategic alliances with well-known enterprises such as ophthalmic medical institutions and educational organizations to carry out joint marketing and product promotions, expanding market coverage.

For our pricing strategy, we will adopt a consumer-friendly pricing approach during the initial phase to lower the purchasing threshold, rapidly capture market share, and build brand loyalty. Subsequently, we will adjust pricing strategies based on market feedback and cost control, introducing various specifications and packages to meet the needs of different consumer segments.

Our partnerships include collaborations with pharmaceutical companies to leverage their sales networks and professional channels to accelerate nationwide product rollout, and collaborations with educational institutions to promote myopia prevention courses in schools, integrating the product into health education systems.

We plan to achieve an average annual growth rate of 15% over the next five years and reach breakeven in the third year. To achieve this goal, we will consolidate our domestic market base while gradually entering international markets such as the Asia-Pacific and Europe. Detailed market entry plans have been formulated, including obtaining international certifications and establishing overseas sales teams. We will continue to increase research and development investment to develop products targeting different eye health needs, such as dry eye prevention and visual fatigue relief, enriching our product portfolio. We aim to sustain ongoing collaborations with globally leading research institutions and pharmaceutical companies to enhance our product's technological level and maintain market competitiveness. Simultaneously, we will strengthen brand promotion efforts to enhance international brand influence, aiming to establish 7-MX as a globally renowned eye health brand.

We have successfully applied for three core patents, ensuring technological exclusivity and establishing competitive barriers. Several authoritative media outlets, such as Health Times and Science and Technology Daily, have conducted in-depth reports on our project, enhancing brand awareness and social influence. We have signed strategic cooperation agreements with multiple well-known domestic pharmaceutical companies and educational institutions to jointly promote product commercialization and marketing. Our team comprises professionals from biomedical science, marketing, and business management, possessing rich experience in research and development as well as commercialization, effectively driving the continuous development of the project.

Recognizing that corporate development is inseparable from societal support, we have integrated social responsibility into our business model. We regularly conduct public welfare projects on myopia prevention, planning to provide free vision screening and health education to over one million adolescents nationwide. Adhering to the concept of green production, we use environmentally friendly materials, reduce carbon emissions, and establish product recycling mechanisms to minimize environmental impact. In addition, we have incorporated the recycling of coffee grounds into our production process, transforming a significant waste byproduct into a valuable resource for caffeine extraction. This initiative not only addresses the global environmental challenge of coffee waste management but also aligns with our commitment to sustainable resource use and environmental stewardship. Through both online and offline channels, we promote scientific eye care knowledge to enhance public awareness of eye health.

Through these initiatives, we are committed not only to providing high-quality products and services but also to making a positive contribution to societal health development. We aim to establish a strong corporate social image and achieve a win-win situation in both economic and social benefits.

Over the next three years, the team will work toward the clear, phased goal of bringing the 7-MX product to market and expanding globally. In 2024, the focus will be on short-term development, primarily mastering the core R&D technology for the product, ensuring that the formulation meets medical standards, and optimizing production processes. By the end of 2024, we plan to conduct pilot studies and gather feedback from a small group of 50 target users to evaluate the product’s initial efficacy and user experience. This feedback will guide further product optimization and help us prepare for larger-scale testing in the following phases. Moving into 2025, the team aims to obtain the necessary production licenses, business permits, and export/import certifications. Additionally, through partnerships with ophthalmology hospitals, research institutes, and businesses, we will further optimize the product's formulation, packaging, and user experience, ensuring successful promotion in the provincial market. From 2026 onwards, as brand awareness increases, the team will expand into national markets and gradually into international markets. We plan to collaborate across borders and participate in international exhibitions, aiming for a 10% annual growth rate over the next three years, with the product reaching 20 countries worldwide.

The potential for market expansion is substantial. The team plans to develop different versions of the 7-MX product based on consumer needs, catering to various age groups and usage scenarios. By 2027, new product lines are expected to contribute a 20% increase in revenue. Meanwhile, we will collaborate with global research institutions to drive technological innovation and product upgrades, ensuring the product remains a leader in the global market. To further enhance market influence, we plan to leverage online and offline advertising, social media marketing, and industry exhibitions, particularly aiming to secure significant market share in the Asia-Pacific and European markets.

As we move forward, the team will face various risks and challenges. Technology leakage and imitation pose major risks to our market position. To mitigate these risks, we plan to implement patent protections, enforce strict confidentiality agreements, and adopt market differentiation strategies. Additionally, increasing market competition will be a challenge, especially in the international arena, where we may encounter competitors with more advanced technologies. To maintain our competitive edge, we will adopt flexible market strategies and focus on long-term brand building and consumer education to enhance market recognition. Talent retention and team stability are also critical to the sustainable development of the project. To address this risk, we plan to implement training programs and incentive mechanisms to ensure the long-term commitment and development of key team members. Moreover, rapid technological advancement and potential substitutes for 7-MX products could threaten the product's market position. Thus, the team will continue to invest heavily in R&D to ensure our technology remains at the forefront of the industry.

In the long term, the promotion of 7-MX products will have a positive impact on society, particularly in the prevention and control of myopia among children and adolescents. By 2030, we expect 7-MX to help reduce the myopia rate by 10% in high-risk regions. To achieve this, the team plans to collaborate with schools and communities across the country to promote awareness of myopia prevention, with a target of reaching 30% of schools and communities nationwide. However, we also recognize the potential negative impact of rapid commercialization, such as being perceived as profit-driven rather than socially responsible. The team will ensure transparency in market operations and a steady approach to development to guarantee that the product genuinely benefits public health.

Furthermore, the project is expected to significantly impact the economy, creating 300 direct jobs by 2027 and generating more than 1,000 jobs in related supply chain industries. In the early stages of international expansion, global economic fluctuations may impact market demand, so we will carefully manage exchange rates and international regulatory risks during cross-border partnerships. On the environmental front, we are committed to reducing carbon emissions through green production processes and recyclable materials. As part of our long-term sustainability strategy, we will integrate the recycling of coffee grounds into our production process, utilizing this abundant waste byproduct for caffeine extraction. This initiative not only addresses the growing environmental concerns related to coffee waste but also reinforces our commitment to sustainable resource management. By converting coffee grounds into valuable resources, we aim to reduce environmental impact and promote circular economy principles. However, in the short term, environmental pressures may lead to higher production costs. Through long-term investment in environmentally friendly practices, we aim to gradually lower these costs and achieve sustainable production goals.

Looking ahead, we aim not only to make breakthroughs in the field of myopia prevention but also to expand into broader health product markets, including specialized medical, sports, and home care sectors. We will collaborate with leading global research institutions and brands to ensure continuous product innovation and upgrades. Although we anticipate uncertainties in the market, technological challenges, and regulatory risks in the future, we are confident that with sustained R&D investment, brand development, and a commitment to social responsibility, the project will achieve long-term success. As part of our expansion and sustainability efforts, we are exploring the utilization of recycled coffee grounds in the production of health products. By converting coffee grounds, an abundant and underutilized byproduct, into valuable resources such as caffeine for medical applications, we aim to integrate circular economy principles into our product development. This initiative not only underscores our dedication to environmental responsibility but also positions us at the forefront of sustainable innovation in health care. Through these efforts, we remain committed to providing sustainable, high-quality products that deliver both social and environmental benefits.